Augpac/Augpac Injection Mechanism of Action

Augpac: Pharmacology: Mechanism of action: The amoxicillin component of the formulation exerts a bactericidal action against many strains of Gram-positive and Gram-negative organisms. The clavulanic acid component has little or no antimicrobial action. It does, however, by inactivation of susceptible beta-lactamase protect amoxicillin from degradation by beta-lactamase enzymes produced by penicillin resistant strains of organisms.
Pharmacokinetics: The pharmacokinetics of amoxicillin and clavulanic acid are closely allied and neither are adversely affected by the presence of food in the stomach, and are stable in the presence of gastric acid. The oral bioavailability of amoxicillin and potassium clavulanate is approximately 90% and 75% respectively.
Peak serum levels of both occur about 1-2 hours after oral administration. Clavulanic acid has about the same plasma elimination half-life (1 hour) as that of amoxicillin (1, 3 hours). Amoxicillin and clavulanate potassium-cl is eliminated primarily unchanged through the renal route (glomerular filtration and tubular secretion). Approximately 50-78% of amoxicillin and 25-40% of clavulanic acid are excreted unchanged in urine within the first 6 hrs. after administration.
Microbiology: Antibacterial Activity: Clavulanic acid is an irreversible inhibitor of beta-lactamases produced by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, H. influenzae, N. gonorrhoeae and B. fragilis (In-vitro activity does not necessarily imply in-vivo efficacy). Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species, Enterobacter, indole positive Proteus, Providencia species and Serratia marcescens.